 
 
Clinical Study Protocol  
EXT608 in Human Healthy Adults; A First -in-Human, 
Randomized, Double -blind, Placebo -controlled, Single Dose 
Escalation Study  
 
Protocol Number:   EXT608 -101  
Version Number:   3.0; 24 October 2022  
Compound:   EXT608  
IND Number :  IND 146180   
Study Phase:    Phase 1  
 
Short Title:  Safety and Tolerability Study of EXT608 in Healthy Participant s  
 
Regulatory Sponsor:  Extend Biosciences Inc., [ADDRESS_894520] : Laura Hales  
   Cell phone ([PHONE_13699]  
 
Medical Monitor :  Poul Strange, MD, PhD  
Cell phone ([PHONE_13700] x7114  
 
  

LH9B8=CG7=9B79G"B7	 CB:=89BH=5@ "' @=B=75@,HI8M)FCHC7C@1-/
(7H C69F 


" "!"#$! 
)FCHC7C@/9FG=CB85H9/9FG=CB
(7HC69F


DDFCJ5@
4444444444444444444444444444444444444444444 4444444444444444444
)CI@,HF5B;9&)< 5H9":BCH=B9"
&98=75@=F97HCF
4444444444444444444444444444444444444444444 4444444444444444444
%9CB,<=)< 5H9":BCH=B9"
,H5H=GH=7=5B
4444444444444444444444444444444444444444444 (7HC69F



%5IF5!5@9G)< 5H9":BCH=B9"
<=9:IG=B9GG(::=79FLH9B8=CG7=9B79G"B7	
444444444444444444444444444444444444444444444444444444444444444444444444444444444
!5555555555555555555555555555555555555@9@9@9@@@@9@9@9@@@@9@9@@@9@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@99@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@G)<Poul StrangeDigitally signed by [CONTACT_662745]: 2022.10.24 15:37:41 -04'00'
LEI SHIDigitally signed by [CONTACT_662746]: 2022.10.24 15:44:20 -04'00'
Extend Biosciences, Inc.  Confidential  IND 146180  3                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
 
INVESTIGATOR SIGNATURE [CONTACT_19841], and 
provides the necessary assurances that this trial will be conducted according to all 
stipulations of the  protocol, including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable regulatory and ICH 
guidelines.  
 
Principal Investigator:  
 
 
[INVESTIGATOR_7496]:   Date:   
 
Print Name:   
______________________________________  
   
  
Extend Biosciences, Inc.  Confidential  IND 146180  4                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
DESCRIPTION OF CHANGES to Protocol v. 3.0 
The protocol was amended per recommendation of FDA to state that all Injection Site 
Reactions, serious and non -serious, will be recorded as Adverse Events.  
Changed text is indicated by [CONTACT_246038] (deleted text).  
Section. 6.4   Injection Site Assessment  
Positive events will furthermore be recorded as AEs . only if they are determined to be 
Serious Adverse Events.  
DESCRIPTION OF CHANGES to Protocol v.2.0  
The protocol was amended to clarify discrepancies between the schedule of procedures 
(Tables 7.1 and 7.1.1) and the text, to correct minor errors and to add a Visual Analog Scale 
for evaluation of injection site pain.  
Changed text is indicated by  [CONTACT_662747] (new text) or strikethrough  (deleted text). In 
addition to the changes shown below, clarifications, minor editorial and formatting changes 
have been made.  
Section 4.[ADDRESS_894521]â€™s lifestyle. Female subjects should be 
surgically sterile (had a bilateral tubal ligation , hysterectomy, bilateral salpi[INVESTIGATOR_1656], 
bilateral oophorectomy, or hysterectomy), postmenopausal (defined as 12 months with 
no menses prior to Screening and a serum follicle stimulating hormone in the 
postmenopausal range at Screening), or, if of child be aring potential, must be non -
lactating and willing to use a highly effective method of birth control for [ADDRESS_894522]â€™s lifestyle. 
May also consider including wording on male sterilization (vasectomy) and sole male 
partner of female subject sterilization (vasectomy).  
Reason for change: The deleted text was included in error in the original protocol . 
Section 6.2.2 Medical History  
The medical history will include: disorders of head, eyes, ears, nose and throat; neoplastic 
and hematological disorders; infectious diseases; disorders of the cardiovascular system 
including hypertension and hyperlipi[INVESTIGATOR_035], each with duration; disorders o f the 
Extend Biosciences, Inc.  Confidential  IND 146180  5                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
respi[INVESTIGATOR_2133]; disorders of the kidney and urinary tract; disorders of the 
gastrointestinal system; disorders of the immune system, connective tissue and joints; 
endocrinology and metabolism with a subcategory for diabetes including year of 
diagnosis, treatment, complications including nephropathy, neuropathy, and retinopathy; 
neurological disorders; and finally alcohol, illicit drug and smoking history including 
duration in years and 20-pack equivalents a day  number of pack years.  
Reason for cha nge: Correction  
 
Section 6.4 Injection Site Assessment  
A Visual Analog Scale (VAS) will be used for evaluation of injection site pain. A 
copy of the VAS is in Appendix 2 . 
 
Reason for change: To provide a standardized measurement of tenderness.  
 
Positive events that are deemed clinically relevant will furthermore be recorded as AEs 
only if the y are determined to be Serious Adverse Events.   
 
Reason for change: Potential injection site reactions are of special interest and thus 
carefully assessed as described above. As asking participants to rate injection site pain 
is a form of solicitation, which results in biased reporting frequencies, non -serious 
injection si te reactions will not additionally be reported as AEs in the present study.   
  
Section [IP_ADDRESS] Urine PD  
Additional pooled urine collections will take place at the following intervals:  
â€¢ Day 1 0: a 4-hour urine collection will begin after dosing.  
â€¢ Day 1 0: from [ADDRESS_894523] b e recorded.  
â€¢ Day 2 1 through Day 3: 12 - hour urine collections.  
 
Reason for change: To be consistent with the Schedule of Procedures with regards to 
naming conventions for study days . 
 
Section 7.1.1: Sequestered Schedule - Footnote 4 and Section 7.2. 5.3 
Time 4 hours  
C-telopeptide of type I collagen  
Reason for change: This test is not required and was included in the original protocol 
in error . 
 
Section [IP_ADDRESS]  â€“ [ADDRESS_894524] :  
Extend Biosciences, Inc.  Confidential  IND 146180  6                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
a. Clinical Chemistry panel and Complete Blood Count  
Sections [IP_ADDRESS] - Day 1, [IP_ADDRESS] - Day 2 and [IP_ADDRESS] - Day 3 :  
Added: Review of concomitant medication  
Reason for change: To be consistent with the Schedule of Procedures in Table 7.1.1 . 
 
Added: Appendix 2 Visual Analog Scale  
Synopsis  
 
Protocol Title:  
EXT608 in Human Healthy Adults; A First -in-Human, Randomized, Double -blind, 
Placebo -controlled, Single Dose Escalation Study  
 
Study Center(s):  
Pharmaceutical Research Associates, Inc.  
[ADDRESS_894525]:   
EXT608 dissolved in a buffered isotonic saline solution  
Starting Dose and Dose Escalation Scheme:  
The starting dose will be 4 Âµg in a volume of 10 ul.  Up to 6 dosing cohorts are planned 
with no single dose escalation to exceed a 3 -fold dose increment.  
 
Route of Administration:  
Subcutaneous (SC) injection  
 
Objectives and Endpoints:  
The primary objective is to characterize the safety and tolerability profile of escalating 
dose levels of EXT608 when administered to healthy adult participants as a single 
injection as assessed by:  
1. Incidence, nature, and severity of adverse events (AEs) and withdrawals due to 
treatment emergent AEs (TEAEs) [Time Frame: Day 0 up to Day 28]  
2. Frequency and severity of post -dose change from baseline in hematology, serum 
chemistries, urinalysis, electrocardiogram (ECG), vital signs, and physical 
examination (E xam) findings [Time Frame: Day 0 up to Day 28]  
3. Percentage of participants with injection site reactions [Time Frame: Day 0 to 
Day 7]  
The secondary objectives are to assess:  
Extend Biosciences, Inc.  Confidential  IND 146180  7                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
1. Single dose PK including AUC 0-24h, AUC 0-48h, AUC 0-28d, AUC 0-â‰ˆ, Cmax, Tmax, TÂ½, 
Æ›z, Cl/F and Vz/F.  
2. Single dose PD by [CONTACT_447] -dose change from baseline in serum chemistries with 
particular attention to Se -Ca, phosphate, magnesium, and creatinine. Urinalysis 
will also be performed.  
Furthermore, the exploratory objectives are to assess:  
1. Single  dose Immunogenicity by [CONTACT_14181] -drug antibodies (ADA) and any neutralizing 
subset (NAb),  
2. Single dose effect on vitamin D metabolism by [CONTACT_11084] 25 -hydroxy -vitamin D and 
1,25-dihydroxy -vitamin D concentrations.  
 
Number of Patients:  
Up to approximately [ADDRESS_894526] (DMB) and ratification by [CONTACT_1034].  
Study Design  
This is a randomized, double -blind, first -in-human (FIH), placebo -controlled single 
ascending dose (SAD) study to study the safety, tolerability, PK, and PD of EXT608 in 
healthy adult participants. Each participan t will provide written informed consent and 
must meet all of the eligibility criteria prior to being randomized and administered study 
product. Participants who discontinue prematurely will be replaced at the discretion of 
the Sponsor . 
Participants will be enrolled into 1 of up to 6 planned single dose cohorts (designated as 
S1 through S6, respectively) in ascending fashion.  
Each cohort will consist of [ADDRESS_894527] a <10% of maximal effect (E max) 
based on allometric scaling of pharmacokinetics (PK) and pharmacodynamics (PD), and 
will be less than  the threshold derived from 1/[ADDRESS_894528] Level (NOAEL) established in GLP toxicology studies. Up to [ADDRESS_894529] -dosing pending review of safety data including Se -Ca 
and adverse events (AEs) by [CONTACT_24318].  
A potential DLT is defined as any of the following EXT608 TEAEs that occurs during 
the DLT period, graded according to the NCI Common Terminology Criteria for Adverse 
Events (CTCAE), Version 5.0 ( 2):  
â€¢ Grade = 3 TEAE  
â€¢ Grade = 3 anemia  
â€¢ Grade = [ADDRESS_894530]/ALT elevation; and/or  
â€¢ Grade = [ADDRESS_894531]/ALT elevation and Grade = 2 Bilirubin elevation  
Extend Biosciences, Inc.  Confidential  IND 146180  8                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
â€¢ Grade = 3 QTc prolongation  
â€¢ Grade = 3 Hyper - and/or Hypotension  
â€¢ Grade = 2 Hyperparathyroidism  
â€¢ Grade = 2 Hyperthyroidism  
â€¢ Grade = 3 Hypercalcemia  
â€¢ Grade = 3 Hypocalcemia  
â€¢ Grade = 3 Hypophosphatemia  
â€¢ Grade = 3 Hypomagnesemia  
â€¢ Grade = 3 Creatinine increased  
Dose escalation decisions will be based on the NCI Common Term inology Criteria for 
Adverse Events (CTCAE), Version 5.0 ( 2) and Se -Ca levels.  
The DMB will review the seven -day safety data in each cohort before aut horizing the 
initiation of the next cohort according to the following decision tree:  
1. No Grade [ADDRESS_894532] on 
Se-Ca will result in the next dose at 2x the previous cohort dose.  
3. A Grade 3 AE suspected related to study drug in a single (n=4) cohort and the 
absence of prohibitive effects on Se -Ca will  result in an additional cohort at the 
same dose.  
4. A single Grade 3 AE suspected related to study drug in 2 cohorts at the same dose 
(n=8) cohort and the absence of prohibitive indication of effects on Se -Ca will 
result in a dose escalation to 1.5x the prev ious dose.  
5. Two or more of the same Grade 3 AE within the same cohort suspected related to 
study drug, or average peak Se -Ca > 1.5 mg/dl above the Upper Limit of Normal 
(ULN) range will terminate dose escalation.  
a. If the last dose escalation was 50% and by [CONTACT_118414] 2 cohorts received 
the previous dose for an n=8, the study will stop.  
b. If the last dose escalation was >50%, the next cohort should receive a dose 
2/3x the previous dose.  
Any DMB recommendation that deviates from the decision tree will be ratif ied by [CONTACT_662748].  
The study schematic is presented in Section 3.2. 
Pending the outcomes of the GLP toxicology and other nonclinical pharmacology studies, 
planned dose levels will be administered by [CONTACT_22666].  
A screening visit will take place within [ADDRESS_894533] 72 hours after dosing for safety and PK assessments 
before discharge. The total confinement period will be 4 nights, unless extended for 
management of AEs at the discreti on of the Investigator. The schedule of  events while 
inpatient  is provided in Section 7.1.1 . Follow -up visits to the clinic will occur on/about 
days 5 , 7, 14, 21 and 28. Participants will be monitored closely during the duration of the 
Extend Biosciences, Inc.  Confidential  IND 146180  9                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
study for safety, PK, and PD assessments as described in Section 3.2. The total duration 
of follow -up period may be modified in the final study design based on safety and PK 
data from non -clinical studies, anticipated PK/PD response and extended in individual 
participants as needed to observe their calcium levels return to concentrations deemed not 
needing further follow up.  
Additional/Alternative PK/PD time points may be implemented if the Sponsor determines 
this is necessary to fully characterize the PK profi le of EXT608.  
 
Eligibility Criteria  
Inclusion Criteria:  
Participants must meet each of the following inclusion criteria to be eligible for 
randomization:  
1. Ability to personally provide written, signed, and dated informed consent to 
participate in the stu dy.  
2. An understanding, ability, and willingness to fully comply with study procedures 
and restrictions.  
3. Male or female between [ADDRESS_894534]â€™s 
lifestyle. Female subjects should be either surgically sterile (had a bilateral tubal 
ligation, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy, or 
hysterectomy), postmenopausa l (defined as 12 months with no menses prior to 
Screening and a serum follicle stimulating hormone in the postmenopausal range 
at Screening), or, if of child bearing potential, must be non -lactating and willing 
to use a highly effective method of birth con trol for [ADDRESS_894535]â€™s lifestyle.  
4. Body mass index between 18.5 and 32 kilogram per square meter (kg/m2), 
inclusive, with a body weight greater than or equal to (>=) 45 kg (9 9 pounds 
[lbs]). This inclusion criterion will only be assessed at the first screening visit.  
5. The participant is in general good medical health with no clinically significant or 
relevant abnormalities, including medical history, physical exam, vital signs , 
ECG, and laboratory evaluations (hematology, chemistry, and urinalysis) as 
assessed by [CONTACT_737].  
6. Willing and able to consume standardized meals during the confinement period of 
the study. All participants will be required to consume the similar meals  and 
Extend Biosciences, Inc.  Confidential  IND 146180  10                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
amounts as practicable  on study days when serial pharmacokinetic (PK) and 
pharmacodynamic (PD) blood samples are collected.  
7. A clinical safety laboratory parameter of hemoglobin greater than (>) 11.7 gram 
per deciliter (g/dl) (females) or 13.1 g/ dl (males) and less than (<) 16 g/dl 
(females) or 17.4 g/dl (males) or, if out of this range, deemed not clinically 
significant by [CONTACT_737].  
8. Total Se -Ca within laboratory normal limits.  
9. Serum parathyroid hormone (PTH) concentration within normal laboratory limits  
at the screening visit only .  
 
Exclusion Criteria:  
Participants are excluded from the study if any of the following exclusion criteria are 
met:  
1. Participant has received any investigational compound within [ADDRESS_894536], or within 5 half -lives, whichever is greater.  
2. Participant is a study site employee or an immediate family member of a study 
site employee.  
3. Participant has evidence of clinically significant (CS) neurologic, cardiovascular, 
pulmonary, hepatic, hematopoietic disease, renal, metabolic, gastrointestinal, 
urologic, immunologic, endocrine disease, serious allergy, allergic skin rash, 
psychiatric disord er, or other abnormality that may impact the ability of the 
participant to participate or potentially confound the study results.  
4. There is any finding in the participantâ€™s medical history, physical exam, or safety 
laboratory tests giving reasonable suspi[INVESTIGATOR_1884] a disease that would contraindicate 
taking EXT608, or a similar drug in the same class, or that might interfere with 
the con duct of the study.  
5. Participant has a known hypersensitivity to any component of the formulation of 
EXT608.  
6. Participant has a positive urine result for drugs of abuse at Screening or Inpatient 
Check -in (Day -1).  
7. Participant has a history of drug abuse (d efined as any illicit drug use) or alcohol 
abuse within 1 year prior to the Screening Visit or is unwilling to agree to abstain 
from alcohol and drugs throughout the study.  
8. Participant is currently using any medication (including over -the-counter [OTC], 
herbal or homeopathic preparations), that, in the opi[INVESTIGATOR_689], 
cannot be discontinued and avoided for 4 weeks (or other time period as noted 
below ) prior to the first dose through 1 month after dose administration. 
Specifically:  
a. 14 days - thiazide diuretics  
b. 30 days - loop diuretics, lithium, systemic corticosteroids (medical 
judgment is required by [CONTACT_737]). Primarily high doses of systemic 
corticosteroids ( i.e., prednisone) should be excluded  
c. 3 months - calcitonin, cinacalcet hyd rochloride, treatment with rhPTH (1 -
84) or N -terminal PTH or PTH -related peptide fragments or analogs  
Extend Biosciences, Inc.  Confidential  IND 146180  11                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
d. For females: changes in hormone replacement therapy within 3 months are 
excluded. Stable (>=3 months) hormone replacement therapy is acceptable  
e. 6 months  - fluoride tablets, oral bisphosphonates, methotrexate, growth 
hormone, digoxin, raloxifene or similar selective estrogen receptor 
modulators (SERMs)  
f. [ADDRESS_894537] result for hepatitis B surface antigen (HBsAg), 
hepatitis C virus (HCV) antibody or a human immunodeficiency virus (HIV) 
infection at Screening.  
13. Participan t has used nicotine -containing products (including but not limited to 
cigarettes, electronic cigarettes, pi[INVESTIGATOR_27442], cigars, chewing tobacco, nicotine patch or 
nicotine gum) within 28 days prior to Inpatient Check -in (Day -1) or a positive 
urine cotinine test a t Screening or Inpatient Check -in (Day -1).  
14. Participant has poor peripheral venous access.  
15. Participant has donated or lost 450 mL or more of their blood volume (including 
plasmapheresis) or had a transfusion of any blood product, within 45 days prior to 
Day 0.  
16. Participant has a Screening or Inpatient Check -in (Day -1) abnormal (CS) ECG. 
Entry of any participant with an abnormal (NCS) ECG must be approved and 
documented by [CONTACT_662749] -
investigator.  
17. Participant  has a resting blood pressure outside the ranges of 90 to 140 mm Hg for 
systolic and 55 to 90 mm Hg for diastolic, confirmed with repeat per Investigator 
discretion, at the Screening Visit or Inpatient Check -in (Day -1).  
18. Participant has a resting heart ra te outside the range 40 to 90 bpm, confirmed with 
repeat per Investigator discretion, at the Screening Visit or Inpatient Check -in 
(Day -1).  
19. Participant has increased CV proarrhythmic potential ( 3): 
a. Participant has a QT interval with Fridericiaâ€™s correction method (QTcF) 
>450 ms or PR outside the range of 120 to 220 ms , confirmed with one 
repeat testing, at the Screening Visit or Inpatient Check -in (Day -1) Visit.  
b. A history of additional risk factors for TdP (e.g., heart failure, 
hypokalemia, family history of Long QT Syndrome).  
c. The use of concomitant medications that prolong the QT/QTc interval.  
20. Participant has abnormal Screening or Inpatient Check -in (Day -1) laboratory 
values that suggest a CS underlying disease or participant with the following 
laboratory abnormalities: ALT and/or AST >1.[ADDRESS_894538], confirmed with on e 
repeat testing.  
21. Participant  is at increased baseline risk for osteosarcoma such as participant with 
Paget's disease of bone or unexplained elevations of alkaline phosphatase, young 
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894539] participation in the study includ es:  
â€¢ Up to a 4 -week screening period  
â€¢ Approximately a 5-day inpatient dosing period  
â€¢ An additional outpatient monitoring of 25 days, for a total study duration of 
approximately 58 days  
 
Statistical Methods  
Sample Size  
The sample size is not determined fo r inferential testing purposes. The sample size of 
4 participants per cohort (3 active: 1 placebo) is considered sufficient for evaluation of 
safety, tolerability, and PD of EXT608 prior to making a decision about dose escalation 
as Se -Ca is very tightly r egulated and determination of effect based on simulations can 
therefore reliably be made with the small sample.  
 
Statistical Analyses  
AEs will be presented in listings and TEAEs will be summarized. Individual results of 
laboratory tests (hematology, chemistry, and urinalysis) will be listed and change from 
baseline will be summarized using shift tables. Individual results of vital signs will be 
listed and observed values and changes from baseline will be summarized.  
Individual results of quantitative ECG parameters from the 12 -lead safety ECGs will be 
listed and observed values and changes from baseline will be summarized and analyzed 
consistent with the ICH E14 ( 3).  
All summaries will be performed by [CONTACT_662750]608 dose level. Placebo data 
will be pooled across cohorts. Ph ysical exam findings will be presented in data listings.  
Concentrations of EXT608 will be summarized by [CONTACT_174378]. Individual plasma concentration data versus time will be 
presented in a data listi ng. PK parameters will be summarized by [CONTACT_154580]. Dose proportionality will be assessed graphically and using a power model. PD 
will be presented in listings and summarized by [CONTACT_134997].  
Detection of ADA and NAbs will be  presented in listings and summarized by [CONTACT_662751].  
No formal hypothesis testing will be conducted as part of this study.  
DMB data packages will be based on the FAS for safety and PP for PK/PD.  
  
Extend Biosciences, Inc.  Confidential  IND 146180  13                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
Table of C ontents  
 
EXT608 in Human Healthy Adults; A First -in-Human, Randomized, Double -blind, 
Placebo -controlled, Single Dose Escalation Study  ................................ .............................  [ADDRESS_894540] of care  ................................ .........................  20 
1.2 Extend Biosciencesâ€™ EXT608  ................................ ................................ ..........  20 
1.3 Rationale for Dose Selection  ................................ ................................ ............  21 
2 Trial Objectives and Purpose  ................................ ................................ ....................  21 
2.1 Primary Objective  ................................ ................................ .............................  21 
2.2 Secondary Objectives  ................................ ................................ .......................  21 
2.3 Exploratory Objectives  ................................ ................................ .....................  21 
3 Trial Design  ................................ ................................ ................................ ..............  22 
3.1 Design Description  ................................ ................................ ...........................  22 
3.1.1  Numbers of Cohorts and Participants, and Treatment Allocation  ..............  22 
3.1.2  Starting Dose  ................................ ................................ ...............................  22 
3.1.3  Staggering of Participants after Dose Escalation (Sentinel Participants)  ... 22 
3.1.4  Dose Limiting Toxicity (DLT) Criteria  ................................ ......................  [ADDRESS_894541] Preparation  ................................ ................................ ..........  31 
5.6.3  Concomitant medications ................................ ................................ ............  32 
5.6.4  Ancillary supplies  ................................ ................................ .......................  32 
5.7 Participant Compliance  ................................ ................................ ....................  32 
6 Procedures and Assessments Description  ................................ ................................ . 32 
6.1 Collection Methodology and Data Flow  ................................ ..........................  32 
6.1.1  Case Report Form (CRF)  ................................ ................................ ............  32 
6.1.2  Electronically uploaded data  ................................ ................................ ....... 32 
6.2 Demographic Variables  ................................ ................................ ....................  32 
6.2.1  Participant identification  ................................ ................................ .............  33 
6.2.2  Medical History  ................................ ................................ ..........................  33 
6.2.3  Concomitant medication  ................................ ................................ .............  33 
6.3 Physical Exam  ................................ ................................ ................................ .. 33 
6.3.1  Complete Physical Exam  ................................ ................................ ............  33 
6.3.2  Directed Physical Exam  ................................ ................................ ..............  33 
Extend Biosciences, Inc.  Confidential  IND 146180  15                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
6.4 Injection Site Assessment  ................................ ................................ .................  33 
6.5 Vital Signs: Pulse, Blood Pressure, Respi[INVESTIGATOR_324723]  ..........  34 
6.6 Weight, Height and Body Mass Index (BMI)  ................................ ..................  34 
6.7 Electrocardiogram (ECG)  ................................ ................................ .................  [ADDRESS_894542]  ................................ ................................ ..................  35 
6.8.2  Urinalysis  ................................ ................................ ................................ .... 35 
6.9 Blood Sample Laboratory Variables  ................................ ................................  36 
6.9.1  Blood Sample Draw  ................................ ................................ ....................  36 
6.9.2  Total Amount of Blood Drawn for Sampling  ................................ .............  36 
6.9.3  Screening and Safety Laboratory Tests  ................................ ......................  36 
6.9.4  Pharmacokinetics (PK)  ................................ ................................ ...............  36 
6.9.5  Pharmacodynamic (PD) variables ................................ ...............................  [ADDRESS_894543] A ccess to Source Data/Documents  ................................ ................................  [ADDRESS_894544]  Aspartate aminotransferase  
AUC 0-24h Area under the curve , zero to 24 hours  
AUC 0-48h Area under the curve, zero to 48 hours  
AUC 0-28d Area under the curve, zero to 28 days 
AUC 0-â‰ˆ Area under the curve, zero to infinity  
BMI  Body Mass Index  
bpm Beats per minute  
BUN  Blood urea nitrogen  
Ca Calcium  
CBC  Complete Blood Count  
Cl/F Apparent clearance  
CRA  Clinical Research Associate  
(e)CRF  (Electronic) Case Report Form. Refers to the online form part of 
the EDC that directly reflects data that is manually entered by [CONTACT_332523].  
CRU  Clinical Research Unit  
CS Clinically significant  
CTCAE  NCI Common Terminology Criteria for Adverse Events  
CV Cardiovascular  
DLT  Dose limiting toxicity  
DMB  Data Monitoring Board  
ECG  Electrocardiogram  
EDC  Electronic Data Capture (application). In addition to the eCRF , 
the EDC may include other items including uploaded files, 
treatment allocation and supply management.  
EDTA  Ethylenediaminetetraacetic acid  
eID Electronic ID  
Emax  Estimated maximal value  of drug levels  in an Emax model  
EoS End of Study  
Exam  Examination  
F Bioavailability  
FAS Full Analysis Set (statistical analysis population)  
FIH First-in-human  
Extend Biosciences, Inc.  Confidential  IND 146180  18                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
GLP  Good Laboratory Practice  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
Hg Mercury; a measurement of pressure  
HIV Human immunodeficiency virus  
ICMJE  Internal Committee of Medical Journal Editors  
IRB Institutional Review Board  
ITT Intent to Treat (statistical analysis population)  
iv Intravenous  
Æ›z Elimination constant  
NAb  Neutralizing antibody  
NCS  Non-clinically significant  
NOAEL  No Adverse Effect Level  
NSAID  Non-steroidal anti -inflammatory drug  
OTC  Over the counter  
PD Pharmacodynamics  
PDF Portable Document Format  
Pbo Placebo  
PK Pharmacokinetics  
PP Per Protocol (statistical analysis population)  
PR A measurement on an ECG of the conduction of the impulse from 
the upper part of the atrium to the ventricle  
PTH  Parathyroid hormone - amino acids 1 -84 (full length)  
QRS  A measurement on an ECG of ventricular depolarization  
QTc  A measurement on an ECG of the duration of ventricular 
depolarization  
QTcF  QTc measurement using Fridericiaâ€™s formula  
RBC  Red Blood Cell count  
RR A measurement on an ECG of the function of the intrinsic 
properties of the sinus node (the time between heart beats)  
SAD  Single Ascending Dose  
SAE  Serious Adverse Event  
sc Subcutaneous  
Se-Ca Serum calcium  
SERM  Selective estrogen receptor modulator  
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894545] (active) drug or control (placebo). The term may refer 
to either.  
T1/2 Serum half -life of a drug; the time it takes for the concentration of 
the drug to be reduced by [CONTACT_662752] ; refers to a  specific  abnormal heart rhythm  
Tmax The time it takes to reach maximum drug concentration  
ULN  Upper Limit of Normal  
VAS  
Vz/F  Visual Analog Scale  
Apparent distribution volume  
WBC  White Blood Cell count with differential count  
 
Extend Biosciences, Inc.  Confidential  IND 146180  20                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
1 Background Information  
1.1 Hypoparathyroidism  
Hypoparathyroidism is a rare clinical syndrome that results from reduced or absent 
parathyroid gland function and is characterized by [CONTACT_662753] (Se -Ca) levels, 
elevated serum phosphorus levels, and absent or inappropriately low levels of parathyroid 
hormone (PTH) in circulation. Hypoparathyroidism is most often caused by [CONTACT_662754] ( i.e., radiation treatment) of the  parathyroid glands, the presence 
of autoimmune or congenital diseases, or low blood plasma magnesium levels. The low 
production of PTH in hypoparathyroidism patients leads to abnormally low calcium 
levels in blood, and an increase of phosphorus in the blo od. 
PTH is secreted in response to low blood Se -Ca levels. To release more ionic calcium 
into the blood, PTH indirectly stimulates bone matrix turnover, enhances renal tubular 
calcium reabsorption, as well as intestinal calcium absorption.  
Patients with hy poparathyroidism most often present with paresthesia, cramps, or tetany, 
but the disorder may also manifest acutely with seizures, bronchospasm, laryngospasm, 
or cardiac rhythm disturbances. In the postsurgical setting, the presentation can be acute 
with t etany, crampi[INVESTIGATOR_007], tachycardia, and altered mental status predominating. Affected 
individuals are most often diagnosed with low blood calcium, magnesium and PTH 
levels, but high phosphorus levels, and frequently show increased urinary calcium 
excretion, whic h can lead to nephrocalcinosis and kidney stones. Hyperphosphatemia can 
be associated with deposition of calcium -phosphate complexes in other soft tissues.  
1.1.[ADDRESS_894546] of care for hypoparathyroidism includes oral c alcium carbonate 
supplements and active forms of vitamin D. Under restrictions, alternative treatment with 
once -daily injections of Parathyroid hormone (rhPTH (1 -84), NatparaÂ®) has been 
approved by [CONTACT_662755]'t be co ntrolled with 
calcium and vitamin D supplements.  
1.2 Extend Biosciencesâ€™ E XT608 
EXT608 is under development as an extended half -life hPTH(1 -34), covalently attached 
to a derivative of vitamin D using the D -VITylationÂ® technology, which results in an 
extended half-life and improved absorption and bioavailability of PTH, aimed at  reducing 
the rate and/or doses of injections. For more information refer to the Investigatorâ€™s 
Brochure ( 1). 
The purpose of this study is to characterize the safety, tolerability, pharmacokinetic (PK), 
and pharmacodynamic (PD) profiles of EXT608 when administered as a single dose to 
healthy adult participant s. EXT608 has undergone a full non -clinical testing program as 
recommended by [CONTACT_662756]. Data from thi s study are intended to identify and select pharmacolog ically 
active dose levels for subsequent dose ranging and other studies  in patients with 
hypoparathyroidism.  
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894547] a <10% of maximal effect (E max) 
based on allometric scaling of pharmacokinetics (PK) and pharmacodynamics (PD), and 
will be less than the threshold derived from 1/[ADDRESS_894548] Level (NOAEL) established in GLP toxicology stud ies. Up to [ADDRESS_894549] clinical study 
conducted in participants with the target indication.  
2.1 Primary O bjective  
The primary objective is to characte rize the safety and tolerability profile of escalating 
dose levels of EXT608 when administered to healthy adult participant s as a single 
injection as assessed by :  
1. Incidence, nature, and severity of adverse events (AEs) and withdrawals due to 
treatment eme rgent AEs (TEAEs) [Time Frame: Day 0 up to Day 28]  
2. Frequency and severity of post -dose change from baseline in hematology, serum 
chemistries, urinalysis, electrocardiogram (ECG), vital signs, and physical 
examination  (Exam)  findings [Time Frame: Day 0 up to Day 28]  
3. Percentage of participant s with injection or infusion site reactions [Time Frame: 
Day 0 to Day 7]  
2.2 Secondary O bjective s 
The secondary objectives are to  assess : 
1. Single dose PK  including AUC 0-24h, AUC 0-48h, AUC 0-28d, AUC 0-â‰ˆ, Cmax, Tmax, TÂ½, 
Æ›z, C l/F and Vz/F . 
2. Single dose PD by [CONTACT_447] -dose change from baseline in serum chemistries with 
particular attention to Se-Ca, phosphate, magnesium , and creatinine . Urinalysis  
will also be performed . 
2.3 Exploratory Objectives  
Furthermore, the exploratory objectives are to assess : 
1. Single dose Immunogenicity by [CONTACT_14181]-drug antibodies (ADA) and any neutralizing 
subset (NAb),  
2. Single dose effect on vitamin D metabolism  by [CONTACT_11084]  25-hydroxy -vitamin D  and 
1,25-dihydrox y-vitamin D concentrations . 
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894550] -in-human (FIH), placebo -controlled single 
ascending dose (SAD) study to study the safety, tolerability, PK, and PD of EXT608 in 
healthy adult participant s. Each participant  will provide written informed  consent and 
must meet all of the eligibility criteria prior to being randomized and administered study 
product . Participant s who discontinue prematurely will  be replaced at the discretion of 
the Sponsor.  
3.1.[ADDRESS_894551] (DMB) and ratification by [CONTACT_1034].  
Participant s will be enrolled into 1 of up to 6 planned single dose cohorts (designated as 
S1 through S6, respectively) in ascending fashion.  
Each cohort will consist of 4 participant s randomized to receive either EXT608 or 
placebo, whereby 3 will receive a single injection of EXT608 and 1 will receive matching 
placebo.  
3.1.2 Starting Dose  
The starting dose will be 4 Âµg in a volume of 10 ul.  Up to 6 dosing cohorts are planned 
with no single dose escalation to exceed a 3 -fold dose increment.  
3.1.3 Staggering of Participants after Dose Escalation  (Sentinel Participants)  
For the first cohort, one participant will be dose d initially. A review of safety data, 
including Se -Ca and adverse events (AEs) for the first [ADDRESS_894552] two participants in the 
cohort will be dosed.   
For subsequent cohorts, t his staggering requirement only applies to cohorts for doses 
higher than previous ly experience d in the study.   
3.1.4 Dose Limiting Toxicity (DLT) Criteria  
A potential DLT  is defined as any of the following EXT608 TEAEs that occurs during 
the DLT period, graded according to the NCI Common Terminology Criteria for Adverse 
Events (CTCAE), Version 5.0 ( 2):  
â€¢ Grade = 3 TEAE  
â€¢ Grade = 3 anemia  
â€¢ Grade = [ADDRESS_894553]/ALT elevation; and/or  
â€¢ Grade = [ADDRESS_894554]/ALT elevation and Grade = 2 Bilirubin elevation  
Extend Biosciences, Inc.  Confidential  IND 146180  23                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
â€¢ Grade = 3 QTc prolongation  
â€¢ Grade = 3 Hyper - and/or Hypotension  
â€¢ Grade = 2 Hyperparathyroidism  
â€¢ Grade = 2 Hyperthyroidism  
â€¢ Grade = 3 Hypercalcemia  
â€¢ Grade = 3 Hypocalcemia  
â€¢ Grade = 3 Hypophosphatemia  
â€¢ Grade = 3 Hypomagnesemia  
â€¢ Grade = 3 Creatinine increased  
3.1.5 Dose Escalation  
Dose escalation decisions will be based on  the NCI Common Terminology Criteria for 
Adverse Events (CTCAE), Version 5.0 ( 2) and Se-Ca levels . 
The DMB will review the seven -day safety data in each cohort before authorizing the 
initiation of the next cohort according to the following decision tree:  
1. No Grade [ADDRESS_894555] on 
Se-Ca will result in the next dose at 2x the previous cohort dose.  
3. A Grade 3 AE suspected related to study drug in a single (n=4) cohort and the 
absence of prohibitive  effects on Se -Ca will result in an additional cohort at the 
same dose.  
4. A single Grade 3 AE suspected related to study drug in 2 cohorts at the same dose 
(n=8) cohort and the absence of prohibitive indication of effects on Se -Ca will 
result in a dose escal ation to 1.5x the previous dose.  
5. Two or more of the same Grade 3 AE within the same cohort suspected related to 
study drug, or average peak Se -Ca > 1.5 mg/dl above the Upper Limit of Normal 
(ULN) range will terminate dose escalation.  
a. If the last dose esca lation was 50% and by [CONTACT_118414] 2 cohorts received 
the previous  dose for an n=8, the study will stop.  
b. If the last dose escalation was >50%, the next cohort should receive a dose 
2/3x the previous dose.  
Any DMB recommendation that deviates from the decision tree will be ratified by [CONTACT_662748].  
The study schematic is presented in Section 3.2. 
3.1.[ADDRESS_894556] within 28 days of dosing. Eligible p articipant s for each 
cohort will be admitted to the Clinical Research Unit (CRU)  [ADDRESS_894557] 72 hours after dosing f or safety and PK assessments 
before discharge. The total confinement period will be 4 nights, unless extended for 
management of AEs at the discretion of the Investigator. The schedule of events while 
Extend Biosciences, Inc.  Confidential  IND 146180  24                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
inpatient  is provided in Section 7.1.1 . Follow -up visits to the CRU will occur on/about 
days 5, 7, 14, 21 and 28. Participant s will be monitored closely during the duration of the 
study for safety, PK, and PD assessments as described in  Section 3.2. The total duration 
of follow -up period may be modified in the final study design based on safety and PK 
data from non -clinical studies, anticipated PK/PD response and extended in individual 
participant s as needed to observe their calcium levels return to concentrations deemed not 
needing further follow up.  
Additional/Alternative PK/PD time points may be implemented if the Sponsor determines 
this is necessary to fully characterize the PK profile of EXT608.  
 
3.[ADDRESS_894558] planned cohort size, the DMB needs e valuable data  up to an d including 
Day 7 for a reliable dose escalation decision. Any participants for whom such data are not 
available will be replaced with a new participant receiving the same treatment assignment 
as the original participant  to ensure the  3:[ADDRESS_894559] meet each of the following inclusion criteria to be eligible for 
randomization:  
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894560]â€™s 
lifestyle. Female subjects should be surgically sterile (had a bilateral tubal 
ligation, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy, or 
hysterectomy), postmenopausal (defined as 12 months with no menses prior to 
Screening and a serum follic le stimulating hormone in the postmenopausal range 
at Screening), or, if of child bearing potential, must be non -lactating and willing 
to use a highly effective method of birth control for [ADDRESS_894561]â€™s lifestyle.  
4. Body mass index between 18.5 and 32 kilogram per square meter (kg/m2), 
inclusive, with a body weight greater than or equal to (>=) 45 kg (99 pounds 
[lbs]). This inclusion criterion will only be assessed at the first  screening visit.  
5. The participant  is in general good medical health with no clinically significant or 
relevant abnormalities, including medical history, physical exam, vital signs, 
ECG, and laboratory  evaluations (hematology, chemistry, and urinalysis) as  
assessed by [CONTACT_941] I nvestigator .  
6. Willing and able to consume standardized meals during the confinement period of 
the study. All participant s will be required to consume similar  meals and amounts 
as practicable on study days when serial pharmacokinetic (PK) and 
pharmacodynamic (PD) blood samples are collected.  
7. A clinical safety laboratory  parameter of hemoglobin greater than (>) 11.7 gram 
per deciliter (g/dl) (females) or 13.1 g/dl (males) and less than (<) 16 g/dl 
(females) or 17.4 g/dl (males) or, if out o f this range, deemed not clinically 
significant by [CONTACT_737].  
8. Total Se -Ca within laboratory  normal limits.  
9. Serum parathyroid hormone (PTH) concentration within normal laboratory limits .  
4.2 Participant  exclusion criteria  
Participant s are excluded from the study if any of the following exclusion criteria are 
met:  
1. Participant  has received any investigational compound within [ADDRESS_894562] , or within 5 half -lives, whichever is greater.  
Extend Biosciences, Inc.  Confidential  IND 146180  27                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
2. Participant  is a study site employee or an immediate family member of a study 
site employee.  
3. Participant  has evidence of  clinically significant  (CS) neurologic, cardiovascular, 
pulmonary, hepatic, hematopoietic disease, renal, metabolic, gastrointestinal, 
urologic, immu nologic, endocrine disease, serious allergy, allergic skin rash, 
psychiatric disorder, or other abnormality that may impact the ability of the 
participant  to participate or potentially confound the study results.  
4. There is any finding in the participant â€™s medical history, physical exam, or safety 
laboratory  tests giving reasonable suspi[INVESTIGATOR_1884] a disease that would contraindicate 
taking EXT608, or a similar drug in the same class, or that might interfere with 
the conduct of the study.  
5. Participant  has a known hypersensitivity to any component of the formulation of 
EXT608.  
6. Participant  has a positive urine result for drugs of abuse at Screen ing or Inpatient 
Check -in (Day -1).  
7. Participant  has a history of drug abuse (defined as any illicit drug use)  or alcohol 
abuse within 1 year prior to the Screening Visit or is unwilling to agree to abstain 
from alcohol and drugs throughout the study.  
8. Participant  is currently using any medication (including over -the-counter [OTC], 
herbal or homeopathic preparatio ns), that, in the opi[INVESTIGATOR_689], 
cannot be discontinued and avoided for 4 weeks (or other time period as noted 
below) prior to the first dose through 1 month after dose administration. 
Specifically:  
a. 14 days - thiazide diuretics  
b. 30 days - loop diuretics, lithium, systemic corticosteroids (medical 
judgment is required by [CONTACT_737]). Primarily high doses of systemic 
corticosteroids (i.e. prednisone) should be excluded  
c. 3 months - calcitonin, cinacalcet hydrochloride, treatment with rhPTH  
(1-84) or N -terminal PTH or PTH -related peptide fragments or analogs  
d. For females: changes in hormone replacement therapy within 3 months are 
excluded. Stable (>=3 months) hormone replacement therapy is acceptable  
e. 6 months - fluoride tablets, oral bispho sphonates, methotrexate, growth 
hormone, digoxin, raloxifene or similar selective estrogen receptor 
modulators (SERMs)  
f. [ADDRESS_894563] result for hepatitis B surface antigen (HBsAg), 
hepatitis C virus (HCV) antibody or a human immunodeficiency virus (HIV) 
infection at Screening.  
13. Participant  has used nicotine -containing p roducts (including but not limited to 
cigarettes, electronic cigarettes, pi[INVESTIGATOR_27442], cigars, chewing tobacco, nicotine patch or 
Extend Biosciences, Inc.  Confidential  IND 146180  28                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
nicotine gum) within 28 days prior to Inpatient Check -in (Day -1) or a positive 
urine cotinine test at Screening or Inpatient Check -in (Day -1).  
14. Participant  has poor peripheral venous access.  
15. Participant  has donated or lost 450 mL or more of their blood volume (including 
plasmapheresis) or had a transfusion of any blood product, within 45 days prior to 
Day 0.  
16. Participant  has a Screen ing or Inpatient Check -in (Day -1) abnormal (CS) ECG. 
Entry of any participant  with an abnormal (NCS) ECG must be approved and 
documented by [CONTACT_662749] -
investigator.  
17. Participant  has a resting blood pressure outside the ranges of 90 to 140 mm Hg for 
systolic and 55 to 90 mm Hg for diastolic, confirmed with repeat per Investigator  
discretion, at the Screening Visit or Inpatient Check -in (Day -1).  
18. Participant  has a resting heart rate outside the range 40 to 90 bpm, confirmed with 
repeat per Investigator  discretion, at the Screening Visit or Inpatient Check -in 
(Day -1).  
19. Participant has increased CV proarrhythmic potential ( 3): 
a. Participant  has a QT interval with Fridericiaâ€™s correction method (QTcF) 
>450 ms (males) or >450 ms (females) or PR outside the range of 120 to 
220 ms, confirmed with one repeat testing, at the Screening Visit or 
Inpatie nt Check -in (Day -1) Visit.  
b. A history of additional risk factors for TdP (e.g., heart failure, 
hypokalemia, family history of Long QT Syndrome).  
c. The use of concomitant medications that prolong the QT/QTc interval.  
20. Participant  has abnormal Screening or Inpatient Check -in (Day -1) laboratory  
values that suggest a CS underlying disease or participant  with the following 
laboratory  abnormalities: ALT and/or AST >1.[ADDRESS_894564], confirmed with one 
repeat testing.  
21. Participant is  at inc reased baseline risk for osteosarcoma such as participant with 
Paget's disease of bone or unexplained elevations of alkaline phosphatase, young 
adult participants with open epi[INVESTIGATOR_269643],  participants with hereditary disorders 
predisposing to osteosarcoma or p articipant with a prior history of external beam 
or implant radiation therapy involving the skeleton are excluded.  
4.[ADDRESS_894565]  
[IP_ADDRESS]  Participant  choice  
Study participant s are free to withdraw from the study at any time at their own initiative.  
Participant s should be instructed in the importance of notifying the site of such a 
decision.  
[IP_ADDRESS]  Investigator determination  
The Investigator may withdraw the participant  at his or her  discretion should further 
participation for medical reasons not be in the participant 's best interest , or for non-
Extend Biosciences, Inc.  Confidential  IND 146180  29                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
compliance with the CRU  rules and requirements . If possible, the Medical Monitor for 
the study should be contact[CONTACT_662757].  
[IP_ADDRESS]  Data Monitoring Board Recommendation  
Potential DLTs as listed in Section 3.1.4  are evaluated by [CONTACT_662758] . 
[IP_ADDRESS]  Sponsor request  
The Sponsor may request discontinuation of any participant  for non -compliance with 
study procedures or other significant protocol violations , and may discontinue the study 
in the case that significant new information becomes available that renders the study 
unsafe or of questionable medical and scientific value t o continue . 
4.3.2 Withdrawal documentation  
In case of withdrawal, the end of study C ase Report Form (CRF)  must be filled out 
including the reasons for the withdrawal, and if possible , a full end of study visit should 
be completed , and as a minimum the Investigat or must evaluate that the participant  is 
clinically stable for release from the study .   
4.3.3 Follow up on withdrawn participant s 
Early discontinuation does not nullify the need to follow adverse events up until 
resolution or stabilization.  
4.4 Non-completer repla cement policy  
Any participants who do not complete and deliver data for a reliable Day 7 assessment 
for review by [CONTACT_662759] s will be replaced with a new 
participant receiving the same treatment assignment as the original participant  after 
discussion and approval by [CONTACT_1034]â€™s Medical Monitor .  
5 Treatment of Participant s 
5.1 Lifestyle  
Participant s will be instructed to continu e to lead their normal lifestyle except they should 
refrain from high intensity aerobic and anaerobic exercise for the duration of the study.   
5.2 Concomitant medications  
5.2.1 Medications for the investigated condition   
Not applicable.  
5.2.2 Other concomitant medications and dietary supplements  
Except as noted in Section 5.2.3 , and Section 4.2 (Exclusion criterion #8) all medication 
and dietary supplements  should be discontinued at least [ADDRESS_894566] 
indistinguishable appearance s. EXT608 injectable solution is stored frozen ( -20Â°C) and 
thawed when ready to use. Thawing should take place at room temperature (~25 Â°C), but 
no higher than body temperature (~37 Â°C), protected from li ght if possible. It is supplied 
as a clear solution in a ready -to-use concentration, single use, glass vial at a concentration 
of 0.4 mg/mL (pH 4.8 -6.2).  The vehicle/placebo solution consists of sterile saline.  
EXT608 is provided as a single dose, glass v ial containing a sterile, clear injectable 
solution in one strength of 0.4 mg/mL.   
5.3.[ADDRESS_894567] or other appropriate individual. Drug accountability records 
indicating the drugâ€™s delivery date to the CRU , inventory at the CRU , use by [CONTACT_6992], 
and return to the Spo nsor (or destruction, if approved by [CONTACT_1034]) will be maintained 
by [CONTACT_47365] . These records will adequately document that the subjects were provided the 
doses as specified in the protocol and should reconcile all study drug received from the 
Sponsor or its designee. Accountability records will include dates, quantities, batch/serial 
numbers, and subject identification numbers. The site monitor will review drug 
accountability at the site on an ongoing basis during monitoring visits.  
5.3.[ADDRESS_894568] or equivalent knows the treatment code .   
The treatment assignment is  computer generated by [CONTACT_662760]. Participants are randomized 3:1 active:control in blocks of 4.  
5.[ADDRESS_894569]. The products will be 
supplied bulk in 2 ml vials each labeled individually with a label that includes:  
1. Product identity  
2. Lot no. and manufacturing date  
3. Recommended storage  (protect from light)  
4. The text: â€œCaution â€“ for Investigational Use Only.â€  
5. Manufacturer and address.  
Storage for both is frozen  at -20â°C or less .  
The products will be logged by [CONTACT_662761], and accounting of all 
dispensed product will be performed . 
5.6.[ADDRESS_894570] and transfer the individual data to the 
Sponsor/CRO. The tables in Section 7.1 describe what data has to be collected when, and 
Section 7.2 outlines the activities in a logical but not mandatory sequence for ease of 
execution.  
6.1 Collection Methodology  and Data Flow  
6.1.1 Case Report Form  (CRF)  
An electronic  CRF  (eCRF)  will be supplied to the investigational site for collection of 
information.  The eCRF is not considered source information and the investigational site 
must have the information available in source documentation.  
6.1.2 Electronically uploaded data  
[IP_ADDRESS]  Participant F iles and Documents  
Participant files  are uploaded in the EDC under the specific participant ID. These files 
may include:   
1. photographs of the injection sites or  
2. lesion from other AEs, or  
3. files from other data collection devices, or  
4. requested copi[INVESTIGATOR_662741] 
(SDV)  
[IP_ADDRESS]   Laboratory Data  
Data from the local laboratory  will be uploaded to the Sponsor /CRO  directly. A test 
report will be sent to the site for inclusion in the participant  chart; this will be considered 
source data.  
6.2 Demograph ic Variables  
Demographic variables including the medical history and current medications will be 
obtained at the screening visit.  All demographic data are entered into the EDC.  
The data to be collected  include : 
Extend Biosciences, Inc.  Confidential  IND 146180  33                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
6.2.1 Participant  identification  
Participant  sex, month and year of birth, and ethnic origin wit h the categories Caucasian,  
African -American, Hispanic, Asian and â€œotherâ€ with a text input field .  
6.2.[ADDRESS_894571] two years in cluding 
completeness of currently ongoing conditions.   
The medical history will include: disorders of head, eyes, ears, nose and throat;  neoplastic 
and hematological disorders; infectious diseases; disorders of the cardiovascular  system  
including  hyperten sion and hyperlipi[INVESTIGATOR_035] , each with duration ; disorders of the 
respi[INVESTIGATOR_2133]; disorders of the kidney and urinary tract; disorders of the 
gastrointestinal system; disorders of the immune system, connective tissue and joints; 
endocrinology and metabolis m with a subcategory for diabetes including year of 
diagnosis, treatment, complications including nephropathy, neuropathy, and retinopathy; 
neurological disorders;  and finally alcohol, illicit drug and smoking history including 
duration in years and number of pack years.  
6.2.[ADDRESS_894572] visit either 
when the participant has co mpleted the full study or at an early termination.   The physical 
exam will include: general appearance; head, eyes, ears, nose, throat, chest, lungs, heart, 
abdomen, musculoskeletal, skin neurological including reflexes.  At the screening  exam, 
any abnormalities found will be recorded in the eCRF under the medical history in the 
appropriate category. Any new findings at the last visit will be captured as an adverse 
event on the CRF for adverse events.  The eCRF will thus not include any spec ific pages 
for physical exam.  
6.3.[ADDRESS_894573] intensity, and  
3. when resolved or stabilized  
will be uploaded in the EDC.  
A Visual Analog Scale (VAS) will be used for evaluation of injection site pain. A copy of 
the VAS is i n Appendix 2 . 
Positive events will furthermore  be recorded as AEs. 
6.5 Vital Signs: Pulse,  Blood Pressure , Respi[INVESTIGATOR_662742], diastolic and systolic blood pressure are measured sitting after five minutes rest. 
Automated instruments may be used.  
Respi[INVESTIGATOR_363819] [ADDRESS_894574] 
1 minute.  
Temperature will be measur ed orally.  
These data are recorded in the EDC.  
6.6 Weight,  Height  and Body Mass Index (BMI)  
Weight is measured with empty pockets and normal indoor clothes without shoes.  Weight 
is measured at several time points according to the  schedule and entered in the ED C. 
Height is measured without shoes an d is only measured at screening and entered in the 
EDC.  
The BMI is calculated by [CONTACT_97937].  
6.7 Electrocardiogram (ECG)  
Equipment for recording the ECG should be recently serviced and calibrated. Machine 
calibration records and performance data should be maintained on file.  
A standard [ADDRESS_894575]. A copy of the recording will be made available for the Sponsor.  
At screening , any abnormalities or normal variants will be assessed for clinical relevance 
and recorded in the medical history. Subsequent changes will be recorded in the EDC 
description text field and deemed clinically relevant or not (separate file s). Changes that 
are deemed clinically relevant  are furthermore recorded as AEs .  
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894576] at Day -1 is performed in the CRU using a commercially available pregnancy kit 
and documented  with a photograph. The binary negative/positive result will be recorded 
in the EDC.  Alternatively, if the turnaround time allows, the test may be sent to the local 
lab. 
6.8.2 Urinalysis  
The sam ple for urinalysis will be sent to the local laboratory  for testing .  
[IP_ADDRESS]  Screening  
At screening, at Day -1, and at the end of study, a complete urinalysis will be done 
including visual inspection of color and clarity, chemical testing for specific gravity, pH, 
bilirubin, urobilinogen, protein, glucose, ketones, blood, leukocytes, nitrite, and 
creatinine.  
[IP_ADDRESS]  Urine PD  
Participants will be instructed to empty the ir bladder prior to sleep. If the participant 
voids during the night, the urine will be collected and pooled with the first morning void. 
The time and volume of urine must be recorded. On Day [ADDRESS_894577] be recorded.  
Additional p ooled urine collections will take pla ce at the following intervals:  
â€¢ Day 0: a 4-hour urine collection will begin a fter dosing . 
â€¢ Day 0: from [ADDRESS_894578] be recorded.  
â€¢ Day 1 through Day 3: [ADDRESS_894579] all urine for 12 hours leading up to the out -patient visits on Days 5, 7, 14 and 28.  
Extend Biosciences, Inc.  Confidential  IND 146180  36                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
Results will be sent to the CRU  and transferred periodically to data management.  
 
6.9 Blood Sample Laboratory  Variables  
6.9.1 Blood Sample Draw  
Blood is drawn either from a phlebotomy , or an indwelling catheter during the inpatient 
period after drawing out minimally 1 ml blood that is discarded per the investigational 
siteâ€™s procedures . 
Samples are drawn into appropriate sample container and processed according to the 
laboratory â€™s instructions.  
6.9.[ADDRESS_894580] visit , which is a period of time of 
approximately 60 days , is well under 5 00 ml, including potentially discarded blood from 
the indwelling catheter sampling procedure described in Section 6.9.1 .  
6.9.3 Screening and Safety Laboratory Tests 
See Sections 7.1 and 7.1.1  for timing of lab tests.  
1. Serum PTH at screening.  
2. Complete blood count  (CBC)  including RBCs, hemoglobin, hematocrit, WBC, 
and platelets, at all scheduled time points.  
a. At screening and end of study , the CBC will also include a differential 
count.  
3. Clinical chemistry comprehensive metabolic panel including serum glucose, 
calcium, albumin, total protein, sodium, potassium, bicarbonate, chloride, blood 
urea nitrogen (BUN), creatinine, alkaline phosphatase, alanine amino transferase 
(ALT), aspartate aminotransferase (AST), total bilirubin.  
4. Hepatitis B, C and HIV  will be tested for at screening .  
a. Hepatitis B surface antigen  
b. Hepatitis C anti body screening test  
c. HIV-1 and HIV -2 antigen and antibody routine screen.  
Anti-Drug Antibody and Neutralizing A ntibod y development Lab reports will be 
reviewed by [CONTACT_662762]. 
6.9.4 Pharmacokinetics ( PK)  
 One 5 ml serum sample  will be collected at the time points noted in Section 7.1.1  and 
divided into 2 aliquots of 1ml  each for determination of E XT608 concentrations . Samples  
will be  shipped to the laboratory  in batches, with one of the samples retained at the site in 
case of transfer problems.  
6.9.5 Pharmacodynamic ( PD) variables  
See Sections 7.1 and 7.1.1  for timing PD labs. Laboratory  PD variables include :  
Extend Biosciences, Inc.  Confidential  IND 146180  37                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
1. Serum total calcium (c orrected for albumin), phosphate, magnesium  at all marked 
time points ,  
2. Serum PTH, creatinine  with estimated GFR , 25-hydroxy -vitamin D (25 -OH-D) 
and 1,25 -dihydroxy -vitamin D ( 1,25-OH-D). 
See Section [IP_ADDRESS]  for urine PD variables.  
6.10    Safety  Variables and Safety Reporting  
6.10.1  Adverse Events  
[IP_ADDRESS]  Adverse Events  
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant  or 
clinical investigation participant  administered a pharmaceutical product and which does 
not necessarily have to have a causal relationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory  
finding, for example), symptom, or di sease temporally associated with the use of a 
medicinal product, whether or not it is considered related to the medicinal product .  
Adverse events will be collected from the time informed consent is signed and until the 
Follow -Up or Early Termination visit .  
All participants will be queried, using non -leading questions, about the occurrence of AEs 
at each study visit. When possible, a constellation of signs and/or symptoms should be 
identified as one overall event or diagnosis. All AEs for randomized subjec ts will be 
recorded in the eCRF and the subject's source documents. Adverse events for subjects who 
are screened but not subsequently randomized in the study will be recorded only in the 
subject's source documents. The following data should be documented f or each AE:  
â€¢ Description of the events  
â€¢ Classification of â€œseriousâ€ or â€œnot seriousâ€  
â€¢ Date of first occurrence and date of resolution (if applicable)  
â€¢ Severity  
â€¢ Causal relationship to study drug  
â€¢ Action taken  
â€¢ Outcome  
â€¢ Concomitant medication or other treatment giv en 
Adverse events  will be rated a mild, moderate or severe intensity using the following 
definitions:  
â€¢ Mild:  â€œMild â€ events are usually transient and do not interfere with the 
participant â€™s daily activities.  
â€¢ Moderate:  â€œModerate â€ events introduce a low level of inconvenience or concern 
to the participant  and may interfere with daily activities.  
â€¢ Severe:  â€œSevere â€ events interrupt the participant â€™s usual daily activit ies. 
 
Extend Biosciences, Inc.  Confidential  IND 146180  38                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
The causality will be rated in the following categories : 
â€¢ Unlikely: An â€œunlikelyâ€ relationship suggests that only a remote connection exists 
between the investigational study product  and the reported AE. Other conditions, 
including chronic illness, progression or expression of the disease state or reaction 
to concomi tant medication, appear to explain the reported AE.  
â€¢ Possible: A â€œpossibleâ€ relationship suggests that the associatio n of the AE with 
the investigational study product  is unknown; however, the AE is not reasonably 
supported by [CONTACT_145037].  
â€¢ Probable: A â€œprobableâ€ relationship suggests that a reasonable temporal 
association  of the AE with study product  functionality  exists and, in the 
Investigatorâ€™s clinical judgment, it is likely that a causal relationship exists 
between the study productâ€™s  functionality  and the AE, and other conditions 
(concurrent illness, progression or expression of disease state or concomitant 
medication reactions) do not appear to explain the AE.  
[IP_ADDRESS]  Adverse Event Outcome  
An AE should be followed until the Investigator has determined and  provided the final 
outcome. The outcome should be classified according to the following categories:  
â€¢ Recovered/resolved: Resolution of an AE with no residual signs or symptoms  
â€¢ Recovered/resolved with sequelae: Resolution of an AE with residual signs or 
symptoms  
â€¢ Not recovered/not resolved (continuing): Either incomplete improvement or no 
improvement of an AE, such that it remains ongoing  
â€¢ Fatal: Outcome of AE is death. â€œFatalâ€ should be used when death is at least 
possibly related to the AE  
â€¢ Unknown: Outcome o f an AE is not known (e.g., subject lost to follow -up) 
[IP_ADDRESS]  Serious Adverse Events  
A serious adverse event is any adverse event that:  
â€¢ Results in death  
â€¢ Is life -threatening (the term â€œlife -threateningâ€ here refers to an event in which the 
participant  was at risk of death at the time of the event; it does not refer to an 
event which hypothetically might cause death if it were more severe)  
â€¢ Requires inpatient hospi[INVESTIGATOR_1081]  
â€¢ Results in persistent or significant disability/incapacity  
â€¢ Is a congenital anomaly/birth defect  
â€¢ Would in the opi[INVESTIGATOR_662743]  
â€¢ May require medical or surgical intervention to prevent one of the outcomes listed 
above  
Extend Biosciences, Inc.  Confidential  IND 146180  39                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
[IP_ADDRESS]  SAE Reporting Procedure  
Serious adverse events will be collected over the same time period as stated above for 
AEs. All SAEs must be reported regardless of the relationship to the  drug. The initial 
report should include at least the following information:  
â€¢ Subjectâ€™s study ID number  
â€¢ Protocol number  
â€¢ Description of the event  
â€¢ Criterion for categorizing the AE as serious  
â€¢ Preliminary assignment of causality to study drug  
Any new informati on should be provided as it becomes available. Copi[INVESTIGATOR_662744], consultant reports, autopsy reports, and any other relevant documents may 
also be requested.  
Appropriate remedial measure should be taken by [CONTACT_144720]/her best 
medical judgment to treat the SAE. These measures and the subjectâ€™s response to these 
measures should be recorded. All SAEs, regardless of relationship to study drug, will be 
followed by [CONTACT_662763]. Clinical, laboratory, and diagnostic measures should be 
employed by [CONTACT_144722].  
The Investigator will be responsible for reporting all SAEs to the Instit utional Review 
Board (IRB)/Ethics Committee (EC). The Sponsor will be responsible for reporting to the 
regulatory authorities.  
Serious adverse events must be reported to the Sponsor within 24 hours of coming to the 
Investigator's attention  Any serious adve rse event that occurs any time after the 
participant  has signed the informed consent form for the study, up to the participant â€™s 
final study visit, inclusive, is to be reported to Product Safety within [ADDRESS_894581] . If unable to enter the SAE information in the EDC ( e.g., 
internet connection is down), the report may be reported by [CONTACT_662764] (609) [ADDRESS_894582] be followed up by [CONTACT_662765].   
Extend Biosciences, Inc.  Confidential  IND 146180  40                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
7 Study Procedures  
7.1 Schedule of procedures  
Period: Screening Check-in8
Day -[ADDRESS_894583] X X
Urine drug screen X X
X
12 hr urine collection X X X X
X X
X X X X X X
X X X X X X XSee In-patient sch. Tolerance (days)ProcedureInpatient Observation Outpatient Follow-up
Days 0-3
See In-patient sch.
Informed consent 
Inclusion/exclusion criteria
Demography and medical history
Concomitant medications
Physical examination 
Height
Weight
Vital signs
ECG
Urine pregnancy test
Urinalysis2
Complete blood count
Clinical chemistry
Injection site assessment
Adverse EventsHepatitis B, C and HIV  screening
Blood samples for PD6
Blood samples for PK
Blood sample for ADA/NAb
Check in to clinic Urine PD7
 
[ADDRESS_894584] morning void.  
8 Additional screening visits for exclusion of SARS -CoV -2 positivity prior to this visit may be added  per the site's procedures  
Extend Biosciences, Inc.  Confidential  IND 146180  41                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
7.1.1 Sequestered  Schedule  
Period Dose
Day Day 0 Day 2 Day 3
Time Unit
Time -120 -90 -30 0 0.25 0.5 1 1.5 2 4 8 12 18 24 36 48 72
15 10 5 0 1 2 5 5 5 10 15 30 30 60 60 60 60
X X X X X X X X X X X X X X X X X
X
X
Randomization X
X X X
X1X1X1
X
X X X X X X X X X X
X X X
X X X X
X X X X
X X X X
X4X X4X X X X4X X4X4
X X X X X X X X X X X X X X X
X X
X
X X X X X X X
X X X X X X X X X X X X XX
Blood samples for PK
Blood sample for ADA/NAbX
Injection of study product
Injection site assessment
Adverse event(s)Blood samples for PD3Sequentered in clinic
Insertion of indwelling catheter
Inclusion/exclusion criteria
Concomitant medication(s)
Physical examination
Weight
Vital signs
ECG
CBC
Clinical ChemistryPooled urine for PD2+/- Tolerance (minutes)ProcedurePre-Dose Post-Dose
Minutes HourDay 1
 
 
1 Directed physical exam only  
2 u-calcium, u -phosphate, u -magne sium, u -bicarbonate, u -sodium,  u-chloride  and u-creatinine . See Section [IP_ADDRESS] for collection times  
3 Total calcium (corrected for albumin), phosphate, magnesium  
4 Additionally, PTH, serum creatinine, 25 -hydroxy -vitamin D (25 -OH-D), 1,25-dihydroxy -vitamin D ( 1,25-OH-D).
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894585] 
be obtained before any other study procedures involving the participant  are 
underta ken. The nature of the risks involved and the tasks the participant  will do 
will be explained.  
2. Throughout the screening process as outlined below, preliminary assessments of 
eligibility are performed whenever new information is available and further 
screen ing abandoned, if the participant is no longer eligible.  
3. The participant â€™s medical history including current conditions  will be obtained . 
For females of current reproductive potential , the history will include current or 
plans of pregnancy , and for males of current reproductive potential , plans of 
conceiving or donating sperm  during the course of or within 3 months of 
completing this study . 
4. The participant â€™s complete use of c oncomitant medications including vitamins , 
herbal supplements  and illicit substances will be obtained  (Section 6.2.3 ). 
5. A physical exam including  temperature, vital signs,  weight and height  will be 
performed  (Sections 6.3.1 , 6.5, and 6.6). 
6. An ECG will be obtained  (Section 6.7). 
7. A fresh midstream urine sample will be obtained and  
a. Sample preparation for laboratory  urinalysis  done  (Section s [IP_ADDRESS]  and 
[IP_ADDRESS] ) 
b. In all females , a urine pregnancy test performed  (Section 6.8.1 ). 
c. A drug and cotinine screen will be performed  
8. A phlebotomy and sample s for testing of:  
a. Complete Blood Count (CBC)  (Section 6.9.3 ) 
b. Clinical Chemistry panel  (Section 6.9.3 ) 
c. HBsAg , HCV  antibody and HIV screening  (Section 6.9.3 ) 
d. PD variables  (Section 6.9.5 ) 
e. ADA/N ab (Section 6.9.3 ) 
will be drawn and processed  (Section 6.9.1 ).  
Extend Biosciences, Inc.  Confidential  IND 146180  43                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
9. The next visit for the check in to the Inpatient  Period will be scheduled when all 
the screening data are anticipated to be available.  If the  siteâ€™s procedures for 
mitigating risk of contagious diseases , including SARS -CoV -2, require additional 
screening and visits prior to the check -in day -1, these are scheduled at the siteâ€™s 
discretion.  
7.2.[ADDRESS_894586] . 
4. Review o f concomitant medication . 
5. A directed physical exam (Section 6.3.2 ) including temperature, vital signs, and 
weight will be performed  (Section 6.5 and 6.6) 
6. An ECG will be obtained  (Section 6.7) 
7. A fresh midstream urine sample will be obtained and  
a. Sample preparation for laboratory  urinalysis done ( Section [IP_ADDRESS]  and 
[IP_ADDRESS] ) 
b. In all females, a urine pregnancy test performed ( Section 6.8.1 ) 
c. A drug and cotinine  screen will be performed  
8. A phlebotomy for testing of:  
a. Complete Blood Count (CBC)  (Section 6.9.3 ), and  
b. Clinical Chemistry panel  (Section 6.9.3 )  
will be drawn and processed .  
9. The pa rticipant  will remain in the CRU , if qualified/ eligible to continue in the 
study . 
10. The participant will be instructed to empty their bladder prior to sleep. If the 
participant voids during the night, the urine will be collected and pooled with the 
first morning void.  The time and volume of urine must be recorded.  
7.2.[ADDRESS_894587] be recor ded.  
[IP_ADDRESS]  Minimally [ADDRESS_894588] an indwelling intr avenous (iv)  catheter in minimally one 
arm and keep it functional per the siteâ€™s procedures.  
a. The iv catheter in the primary arm is to ensure iv access availability 
should this be needed in case of something unexpected happening in this 
first-in-human stud y. 
b. The iv catheter in the secondary is for blood sampling , should this method 
be preferred over repetitive phlebotomies.  
Extend Biosciences, Inc.  Confidential  IND 146180  44                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
2. Eligibility criteria are checked and if all are met the participant is randomized  
(Section 5.5) 
3. Study product made ready for injection at the scheduled time.  
[IP_ADDRESS]   [ADDRESS_894589]  (+/- 10 min)  
1. Vital sign s are measured  (Section 6.5) 
2. Blood sample s for testing of:  
a. Clinical Chemistry panel  and Complete Blood Count  (Section 6.9.3 ) 
b. PK (Section 6.9.4 ) 
c. PD variables ( Section 6.9.5 ) 
d. ADA/Nab ( Section 6.9.3 ) 
will be drawn , processed  and date and time stamp for draw time noted .  
3. The participant will remain in the CRU . 
[IP_ADDRESS]    [ADDRESS_894590]  (+/- 5 min)  
1. A blood sample for testing of:  
a. PK (Section 6.9.4 ) 
will be drawn , processed  and da te and time stamp for draw time noted.  
2. The participant will remain in the CRU.  
[IP_ADDRESS]  Time 0  
1. The planned injection site in the abdomen is assessed for any abnormalities or 
unusual appearance and a baseline photograph taken  (Section 6.4). This may be 
performed within [ADDRESS_894591] Hour after Injection  
[IP_ADDRESS]  Time  15 minutes  (+/- 1 min)  
1. A blood sample for testing of:  
a. PK (Section 6.9.4 ) 
will be drawn , processed  and date and time stamp for draw time noted . 
2. The injection site in the abdomen is assessed for any reactions and a photograph 
taken,  if there is any reaction  (Section 6.4) 
3. Any adverse events will be recorded  (Section 6.10.1 ) 
4. The participant remains under observation in the CRU.  
[IP_ADDRESS]  Time 30 minutes  (+/- 2 min)  
1. A blood sample for testing of:  
b. PK (Section 6.9.4 ) 
will be drawn , processed  and date and time stamp for draw time noted  
Extend Biosciences, Inc.  Confidential  IND 146180  45                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
2. Any adverse events will be recorded  (Section 6.10.1 ) 
3. The participant remains under observation in the CRU.  
[IP_ADDRESS]  Time 1 hour  (+/- 5 min)  
1. Vital sign s are measured ( Section 6.5) 
2. A fresh midstream urine sample will be obtained and  
a. sample preparation for laboratory  urinalysis done ( Section [IP_ADDRESS]  item 1 
only)  
3. Blood samples for testing of:  
a. PK (Section 6.9.4 ) 
b. PD variables ( Section 6.9.5 , item 1 only ) 
will be drawn , processed  and date and time stamp for draw time noted .  
4. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any rea ction ( Section 6.4) 
5. Any adverse events will be recorded ( Section 6.10.1 ) 
6. The participant will remain in the CRU.  
7.2.5 Day 0 from 1 Hour after Injection  
[IP_ADDRESS]  Time 1.5 hours  (+/- 5 min)  
The analogous procedures to the visit at time =  30 minutes are executed.  
[IP_ADDRESS]  Time 2 hours  (+/- 5 min)  
The analogous procedures to the visit at time =  30 minutes are executed.  
[IP_ADDRESS]  Time 4 hours  (+/- 10 min)  
The analogous procedures to the visit at time =  1 hour are executed , with the addition of 
25-hydroxy -vitamin D (25 -OH-D), 1,25-dihydroxy -vitamin D (1,25 -OH-D). 
A pooled urine collection will begin and continue until bedtime. The time of each void 
and total volume will be recorded.  
[IP_ADDRESS]  Time 8 hours  (+/- 15 min)  
The analogous procedures to the visit at time =  1 hour  are executed w ith the exception of 
the injection site assessment.  
[IP_ADDRESS]  Time 12 hours  (+/- 30 min)  
The analogous procedures to the visit at time =  [ADDRESS_894592] be recorded.  
[IP_ADDRESS]  Time 18 hours  (+/- 30 min)  
The analogous procedures to the visit at time =  8 hours  are executed.   
Extend Biosciences, Inc.  Confidential  IND 146180  46                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
7.2.6 Days 1 through 3 of the Inpati ent Period  
[IP_ADDRESS]  Day 1 , 24 hours after the injection  (+/- 1 hr)  
1. A directed physical exam ( Section 6.3.2 ) including temperature and vital signs 
will be performed (Section 6.5 and 6.6) 
2. Review of concomitant medication  
3. An ECG will be obtained ( Section 6.7) 
4. Blood samples  for testing of:  
a. Complete Blood Count (CBC) ( Section 6.9.3 ) 
b. Clinical Chemistry panel ( Section 6.9.3 ) 
c. PK (Section 6.9.4 ) 
d. PD variables ( Section 6.9.5 ) 
will be drawn , processed  and date and time stamp for draw time noted .  
5. A [ADDRESS_894593] be recorded.  
6. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any reaction ( Section 6.4) 
7. Any adverse events will be recorded ( Section 6.10.1 ) 
8. The participant will remain in the CRU.  
[IP_ADDRESS]  Day 1, 36 hours after the injection  (+/- 1 hr)  
1. Vital signs are measured ( Section 6.5), 
2. Blood samples for testing of:  
a. PK (Section 6.9.4 ) 
b. PD variables ( Section 6.9.5 , item 1 only ) 
will be drawn , processed  and date and time stamp for draw time noted .  
3. A [ADDRESS_894594] be recorded.  
4. Any adverse events will be recorded ( Section 6.10.1 ) 
5. The participant will remain in the CRU.  
[IP_ADDRESS]  Day 2 , 48 hours after Injection  (+/- 1 hr)  
1. A directed physical exam ( Section 6.3.2 ) including temperature, and vital signs 
will be performed (Section 6.5 and 6.6) 
2. Review of concomitant medication  
3. An ECG will be obtained ( Section 6.7) 
4. Blood samples for testing of:  
a. Complete Blood Count (CBC) ( Section 6.9.3 ) 
b. Clinical Ch emistry panel ( Section 6.9.3 ) 
c. PK (Section 6.9.4 ) 
d. PD variables ( Section 6.9.5 ) 
will be drawn , processed  and date and time stamp for draw time noted .  
4. A [ADDRESS_894595] be recorded.  
5. Any adverse events will be recorded ( Section 6.10.1 ). 
Extend Biosciences, Inc.  Confidential  IND 146180  47                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
The participant will remain in the CRU.  
[IP_ADDRESS]  Day 3 , 72 hours after Injection  (+/- 1 hr)  
1. A directed physical exam ( Section 6.3.2 ) including temperature, vital signs and 
weight will be performed (Section 6.5 and 6.6) 
2. Review of concomitant medication  
3. An ECG will be obtained ( Section 6.7) 
4. Blood samples for testing of:  
a. Complete Blood Count (CBC) ( Section 6.9.3 ) 
b. Clinical Ch emistry panel ( Section 6.9.3 ) 
c. PK (Section 6.9.4 ) 
d. PD variables ( Section 6.9.5) 
e. ADA/Nab ( Section 6.9.3 ) 
will be drawn , processed  and date and time stamp for draw time noted . 
5. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any reaction ( Section 6.4) 
6. Any adverse events will be recorded ( Section 6.10.1 ) 
7. If the participantâ€™s Se-Ca incr eased â‰¤ 5%, or increased  >5% and no longer 
increase s, and their  clinical  condition is stable, the participant is discharged from 
the clinic  at the investigatorâ€™s discretion  after:  
a. If not scheduled already, a n appointment from the Day [ADDRESS_894596] all urine for 12 -hours prior to the  next 
outpatient visit.  
7.2.7 Outpatient Follow -up 
[IP_ADDRESS]  Day 5  
1. The participant checks into the CRU before 10 am.  
2. Review of concomitant medication  
3. A directed physical exam ( Section 6.3.2 ) including temperature, and vital signs 
will be performed (Section 6.5 and 6.6). 
4. A fresh midstream urine sample will be obtained and  
a. Sample preparation for laboratory  urinalysis done ( Section [IP_ADDRESS]  only)  
5. Blood samples for testing of:  
a. Complete Blood Count (CBC) ( Section 6.9.3 ) 
b. Clinical Chemistry panel ( Section 6.9.3 ) 
c. PK (Section 6.9.4 ) 
d. PD variables ( Section 6.9.5 ) 
will be drawn , processed  and date and time stamp for draw time noted .  
6. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any reaction ( Sectio n 6.4). 
7. Any adverse events will be recorded ( Section 6.10.1 ). 
Extend Biosciences, Inc.  Confidential  IND 146180  48                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
8. If the participantâ€™s condition is stable, the participants is discharged from the 
clinic at the investigatorâ€™s discretion after  
a. if not scheduled already, an  appointment from the Day [ADDRESS_894597] all urine for 12 -hours prior to the next outpatient visit.  
 
[IP_ADDRESS]  Day 7  (+/- 1 day)  
1. The participant checks into the CRU before 10 am.  
2. Changes in concomitant medication are reviewed.  
3. A directed physical exam ( Section 6.3.2 ) including temperature, vital signs and 
weight will be performed  Section 6.5 and 6.6). 
4. A fresh midstream urine sample will be obtained and  
a. Sample preparation for laboratory  urinalysis done ( Section [IP_ADDRESS]  only)  
5. Blood samples for testing of:  
a. Complete Blood Count (CBC) ( Section 6.9.3 ) 
b. Clinica l Chemistry panel ( Section 6.9.3 ) 
c. PK (Section 6.9.4 ), 
d. PD variables ( Section 6.9.5 ) 
e. ADA/Nab ( Section 6.9.3 ) 
will be drawn , processed  and date and time stamp for draw time noted .  
6. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any reaction ( Section 6.4). 
7. Any adverse events will be recorded ( Section 6.10.1 ). 
8. If the participantâ€™s condition is stable, the participants is discharged from the 
clinic at the investigatorâ€™s discretion after  
a. if not scheduled already, an  appointment from the Day [ADDRESS_894598] all urine for 12 -hours prior to the next outpatient visit.  
 
[IP_ADDRESS]  Day 14  (+/- 1 day)  
1. The participant checks into the C RU before 10 am.  
2. Changes in concomitant medication are reviewed.  
3. A directed physical Exam ( Section 6.3.2 ) including temperature, and vital signs 
will be performed (Section 6.5 and 6.6). 
4. Blood samples for testing of:  
a. Complete Blood Count (CBC) ( Section 6.9.3 ) 
b. PK (Section 6.9.4 ) 
c. PD variables ( Section 6.9.5 ) 
Extend Biosciences, Inc.  Confidential  IND [ADDRESS_894599] aw time noted .  
5. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any reaction ( Section 6.4). 
6. Any adverse events will be recorded ( Section 6.10.1 ). 
7. If the participantâ€™s condition is stable, the participants is discharged from the 
clinic at the inve stigatorâ€™s discretion after  
a. if not scheduled already, an  appointment from the Day [ADDRESS_894600] the CRU should any health 
problems emerge.  
[IP_ADDRESS]  Day 21  (+/- 2 days)  
The analogous procedures to the visit at day [ADDRESS_894601] all urine for 12 -hours prior to the next outpatient visit  
[IP_ADDRESS]  Day 28 (+/- 2 days) Last visit to clinic  or Early Termination  Visit  
1. The participant checks into the CRU before 10 am.  
2. Changes in concomitant medication are reviewed.  
3. A complete physical exam ( Section 6.3.1 ) including tempe rature, vital signs and 
weight will be performed (Section 6.5 and 6.6). 
4. A fresh midstream urine sample will be obtained and  
a. sample preparation for laboratory  urinalysis done ( Section 6.8.2 ), 
a. and, in females of reproductive potential only, a urine pregnancy test 
performed ( Section 6.8.1 ). 
5. Blood samples for testing of:  
a. Complete Blood Count (CBC)  including differential count  (Section 6.9.3 ) 
b. Clinical Chemistry panel ( Section 6.9.3 ) 
c. PK (Section 6.9.4 ) 
d. PD variables ( Section 6.9.5 ) 
e. ADA/Nab ( Section 6.9.3 ) 
will be drawn , processed  and date and time stamp for draw time noted .  
6. The injection site in the abdomen is assessed for any reactions and a photograph 
taken, if there is any reaction ( Section 6.4). 
7. Any adverse events will be recorded ( Section 6.10.1 ). 
8. The participant is discharged from the study.  
7.2.[ADDRESS_894602]  
A DMB will be formed to monitor safety and dose cohort choices and provide 
recommendations to the Sponsor for implementation in the study. The DMB will 
minimally include an independent Safety Monitor, the Medical Monitor, the 
Investigator( s), and an independent statistician as voting members, as well as a non -
voting coordinator. Operational details will be described in a Safety Plan.  
7.3.[ADDRESS_894603] participant of a cohort has completed Day 7 and evaluable data are 
available,  statistics will provide a data summary of the cohort data for the DMB. The 
DMB will meet and decide further actions as described in the Safety Plan.  
 
8 Statistical Methods  
8.1 Sample size  
The sample size is not determined for inferential testing purposes. The s ample size of 4 
participants per cohort (3 active: 1 placebo) is considered sufficient for evaluation of 
safety, tolerability, and PD of EXT608 prior to making a decision about dose escalation 
as Se -Ca is very tightly regulated and determination of effect based on simulations can 
therefore reliably be made with the small sample.  
8.2 Analysis populations  
Two participant populations will be defined. The Safety  of Full Analysis Set population 
(FAS) will be defined as all participants who are randomized. The Per-Protocol  (PP) 
population will be participants for whom evaluable data to and including Day 7 is 
available and with no major protocol violations.   
8.3 Data Analysis  
AEs will be presented in listings and Treatment Emergent Adverse Events (TEAEs) will 
be summariz ed. Individual results of laboratory tests (hematology, chemistry, and 
urinalysis) will be listed and change from baseline will be summarized using shift tables. 
Individual results of vital signs will be listed and observed values and changes from 
baseline  will be summarized.  
Individual results of quantitative ECG parameters from the 12 -lead safety ECGs will be 
listed and observed values and changes from baseline will be summarized and analyzed 
consistent with the ICH E14 ( 3).  
All summaries will be performed by [CONTACT_662750]608 dose level. Placebo data 
will be pooled across cohorts. Physical exam findings will be presented in data listings.  
Concentrations of EXT608 will be summarized by [CONTACT_174378]. Individual plasma concentration data versus time will be 
presented in a data listing. PK parameters will be summarized by [CONTACT_662766], Inc.  Confidential  IND 146180  51                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
statistics. Dose proportionality will be assessed graphically and using a po wer model. PD 
will be presented in listings and summarized by [CONTACT_134997].  
Detection of ADA and NAbs will be presented in listings and summarized by [CONTACT_662751].  
No formal hypothesis testing will be conducted as part of this study.  
DMB d ata packages will be based on the FAS for safety and PP for PK/PD.  
Further details are described in the Statistical Analysis Plan.  
 
[ADDRESS_894604] Access to Source Data/Documents  
Extend Biosciences, Inc. or agents thereof, the reviewing IRB/EC, and health authorit ies 
from the US or other countries will have access to source documents at the 
investigational site for monitoring, auditing or inspection purposes.  
 
10   Quality Control and Quality Assurance  
10.1   Monitoring  
The study will be monitored by [CONTACT_662767].  
Monitoring will be done via on -site visits by [CONTACT_25007], who will review the eCRFs 
and source documents, and via remote review of eCRF entries.  The site monitor will 
make sure that the investigation is conducted a ccording to protocol design, GCP, and 
regulatory requirements.  
Alternatively, due to the ongoing SARS -CoV -2 pandemic, all monitoring may be remote 
using a combination of source documents uploaded to the EDC and other tools for 
viewing site documents, e.g.,  for signed ICFs, for SDV. Further details will be described 
in a Clinical Monitoring Plan.  
10.2   Data Management  
Data will be entered in the electronic data capture (EDC) system at the investigational 
site.   
The data management plan will describe the methods  used to collect, check, validate, and 
process clinical data in detail.  It will also clarify the roles and responsibilities for the 
different functions and personnel involved in the data management process.   
AEs and medical/surgical history will be class ified according to the terminology of the 
Medical Dictionary for Regulatory Activities (MedDRA; version specified in the Data 
Management Plan).  Medications will be classified according to the latest World Health 
Organization (WHO) Drug Dictionary.  
Quality  control procedures will be applied to each stage of data handling to ensure that all 
data are reliable and have been processed correctly.  When all data have been coded, 
validated, and locked, clean file will be declared.  Any treatment -revealing data may  
thereafter be added and the final database will be locked.  
Extend Biosciences, Inc.  Confidential  IND 146180  52                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
 
10.2.1  Audits  
In addition to monitoring, the Sponsor, Sponsorâ€™s representative, US or foreign 
regulatory authorities, and/or the reviewing IRB/ethics committee, may audit the conduct 
of the study.  The auditors must have access to all study documents, the facilities where 
the study was conducted, and the study staff for interviews.  The investigator will contact 
[CONTACT_12559] a regulatory agency about an inspection at the 
center.  
 
11   Ethics  
The study will be performed in accordance with applicable regulatory requirements, the 
International Council for Harmonisation (ICH) guideline for Good Clinical Practice 
(GCP), and the ethical principles that have their origins in the Declaratio n of Helsinki.  
An IRB will approve the final study protocol, including the final version of the informed 
consent form and any other written information and/or materials to be provided to the 
subjects, before any subjects are enrolled.  The investigator wil l ensure the distribution of 
these documents to the applicable IRB/EC and to the staff of the study site.  
11.[ADDRESS_894605] keep the study documentation for 15 years after the comp letion of 
the study.  
 
13   Publication Policy  
The Sponsor intends to publish the findings of the study and in general follows the 
guidelines set forth by [CONTACT_662768] (ICMJE) (6). 
The investigator may publish the data from the site one year after the last participant 
finished the study.  
  
Extend Biosciences, Inc.  Confidential  IND 146180  53                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
 
14   References  
1. EXT608 Investigatorâ€™s Brochure  
2. NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. 
https://ctep.cancer.gov/protocoldevelopment/electronic_app lications/docs/CTCA
E_v5_Quick_Reference_8.5x11.pdf  Accessed 23 -Sep-2020 . 
3. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic 
Potential for Non -Antiarrhythmic Drugs. October 2005. 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/e14 -
clinical -evaluation -qtqtc -interval -prolongation -and-proarrhythmic -potential -non-
antiarrhythmic -0 . Accessed 26 -Sep-2020  
4. American Association for Clinical Chemistry https://labtestsonline.org/tests -index   
5. Mayo Clinic Laboratories https://www.mayocliniclabs.com/test -catalog/  
6. ICMJE. Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals: Writing and Editing for Biomedical Publication.  www icmje org 2020 
October 10; Available from: URL: www.icmje.org  
  
Extend Biosciences, Inc.  Confidential  IND 146180  54                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
15   Appendix 1 
 CLINICAL LABORATORY TESTS  
 
See Section s 7.1 and 7.1.1  for timing of tests  
 
Laboratory 
Assessments  Parameters  
Hematology  Complete blood count (CBC) including RBCs, hemoglobin, hematocrit, 
WBC, and platelets, at all scheduled time points.  
At screening and end of study, the CBC will also include a differential 
count.  
Clinical 
Chemistry  Serum glucose, calcium, albumin, total protein, sodium, potassium, 
bicarbonate, chloride, blood urea nitrogen (BUN), creatinine, alkaline 
phosphatase, alanine amino transferase (ALT), aspartate 
aminotransferase (AST), total bilirubin  
Serology  Hepatitis B surface antigen (HBsAg), Hepatitis C vi rus (HCV), Human 
immunodeficiency virus (HIV)  
Urinalysis  Color and clarity, chemical testing for specific gravity, pH, bilirubin, 
urobilinogen, protein, glucose, ketones, blood, leukocytes, nitrite, and 
creatinine  
Serum PD 
assessments  Serum PTH, Total  calcium, Phosphate, Magnesium, Serum creatinine, 
25-hydroxy -vitamin D (25 -OH-D), 1,25-dihydroxy -vitamin D (1,25 -
OH-D) 
Urine PD  u-calcium, u -phosphate, u -magnesium, u -bicarbonate, u -sodium, and u -
chloride  and u -creatinine.  
Other Tests  Urine drug screen  
Urine cotinine  
Serum or urine pregnancy test  
 
  
Extend Biosciences, Inc.  Confidential  IND 146180  55                  Clinical Study Protocol EXT608 -101, V 3, 24 October  2022   
 
16     Appendix 2  
 
Visual Analog Scale  
 
Please draw a single vertical line  through the scale below that corresponds to the 
intensity (severity) of any pain you are feeling right now .  
 
To indicate â€œno painâ€ or â€œworst possible painâ€ please circle  the words instead of marking 
on the line.  
 
 
   
 
 
 
 Worst possible pain  No pain  